Furthermore, the involvement of cyclin E and MnSOD in cell resistance to doxorubicin suggests that therapeuthical strategies (i.e. antisense or chemical inhibitors) targeting cyclin E/CDK (Sausville et al, 2000) or SOD activities (Huang et al, 2000) could also be tested as chemosensitising tools to anthracycline treatment in cyclin E-overexpressing tumours. The gene discussed is SOD2; the disease is neoplasm.